Recently, Zhou et al. report the use of nanoparticles loaded with sorafenib which reduce tumor hypoxia and trigger the immune response, and when combined with anti-PD-L1 immunotherapy, was able to prevent tumor growth and inhibit metastasis in hepatocellular carcinoma [235]. This evidence concerns the gene CD274 and neoplasm.